Detection of autoantibodies to potentially amyloidogenic protein, gamma-synuclein, in the serum of patients with amyotrophic lateral sclerosis and cerebral circulatory disorders
- Autores: Roman A.Y.1,2, Kovrazhkina E.A.3, Razinskaya O.D.3, Kukharsky M.S.1, Maltsev A.V.1, Ovchinnikov R.K.1, Lytkina O.A.1, Smirnov A.P.3, Moskovtsev A.A.4, Borodina Y.V.5, Surguchov A.P.6, Ustyugov A.A.1, Ninkina N.N.1,4, Skvortsova V.I.3
-
Afiliações:
- Institute of Physiologically Active Compounds
- Aix-Marseille Université
- Pirogov Russian National Research Medical University
- Research Institute of General Pathology and Pathophysiology
- Research Center Hospital
- University of Kansas Medical Center
- Edição: Volume 472, Nº 1 (2017)
- Páginas: 64-67
- Seção: Biochemistry, Biophysics, and Molecular Biology
- URL: https://journals.rcsi.science/1607-6729/article/view/211826
- DOI: https://doi.org/10.1134/S1607672917010197
- ID: 211826
Citar
Resumo
In this study, we analyzed serum for the presence of antibodies to gamma-synuclein in patients with amyotrophic lateral sclerosis (ALS) compared to the control group of patients with other neurological diseases and healthy control donors. As a result, antibodies against gamma-synuclein are not an ALS-specific feature and have been identified in patients with ALS as well as in the control group patients. Patients with the impaired cerebral circulation showed increased incidence of autoantibodies to gamma-synuclein, yet the difference lacks statistical representativeness due to limited sample size.
Sobre autores
A. Roman
Institute of Physiologically Active Compounds; Aix-Marseille Université
Email: maltsevandro@mail.ru
Rússia, Chernogolovka, Moscow oblast, 142432; Inserm
E. Kovrazhkina
Pirogov Russian National Research Medical University
Email: maltsevandro@mail.ru
Rússia, Moscow, 117997
O. Razinskaya
Pirogov Russian National Research Medical University
Email: maltsevandro@mail.ru
Rússia, Moscow, 117997
M. Kukharsky
Institute of Physiologically Active Compounds
Email: maltsevandro@mail.ru
Rússia, Chernogolovka, Moscow oblast, 142432
A. Maltsev
Institute of Physiologically Active Compounds
Autor responsável pela correspondência
Email: maltsevandro@mail.ru
Rússia, Chernogolovka, Moscow oblast, 142432
R. Ovchinnikov
Institute of Physiologically Active Compounds
Email: maltsevandro@mail.ru
Rússia, Chernogolovka, Moscow oblast, 142432
O. Lytkina
Institute of Physiologically Active Compounds
Email: maltsevandro@mail.ru
Rússia, Chernogolovka, Moscow oblast, 142432
A. Smirnov
Pirogov Russian National Research Medical University
Email: maltsevandro@mail.ru
Rússia, Moscow, 117997
A. Moskovtsev
Research Institute of General Pathology and Pathophysiology
Email: maltsevandro@mail.ru
Rússia, Moscow, 125315
Yu. Borodina
Research Center Hospital
Email: maltsevandro@mail.ru
Rússia, Chernogolovka, Moscow oblast
A. Surguchov
University of Kansas Medical Center
Email: maltsevandro@mail.ru
Estados Unidos da América, Kansas
A. Ustyugov
Institute of Physiologically Active Compounds
Email: maltsevandro@mail.ru
Rússia, Chernogolovka, Moscow oblast, 142432
N. Ninkina
Institute of Physiologically Active Compounds; Research Institute of General Pathology and Pathophysiology
Email: maltsevandro@mail.ru
Rússia, Chernogolovka, Moscow oblast, 142432; Moscow, 125315
V. Skvortsova
Pirogov Russian National Research Medical University
Email: maltsevandro@mail.ru
Rússia, Moscow, 117997
Arquivos suplementares
